Finding a new biomarker in astrocytoma

• Main Authors: Hung-Pei Tsai, 蔡鴻培
• Other Authors: Aij-Lie Kwan
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/17531176240488986175

博士 === 高雄醫學大學 === 醫學研究所博士班 === 105 === Astrocytoma is the most common glioma in central nervous system. According to WHO tumor classification, astrocytoma was classified into I ~ IV grade. Grade IV astrocytoma is a highly malignant tumor. In the past, the patients had a poor prognosis after chemotherapy, radiotherapy and surgical. The survival time is over two years of less than 5%. In astrocytoma, it is difficult to determine prognosis of the patient through WHO grade. Therefore, in this study, we use Aurora A, LC3B, NPM, p53, EGFR, Sp1, Fli-1, Galectin-3 and GSK3Β, transcription factors, and related proteins to explore the clinical role these proteins in clinical role in astrocytoma. First, we collected the patients with clinical data (such as age, sex, KPS, time of recurrence, survival time, tumor size, and radiation therapy) and paraffin section of astrocytoma which surgically removed in Kaohsiung Medical University Chung-Ho Memorial Hospital. The expression of Aurora A, LC3B, NPM, p53, EGFR, Sp1, Fli-1, Galectin-3 and GSK3B and WHO tumor grade and survival time were confirmed by immunohistochemical staining and clinical parameters with ch-square and K-M survival. The results showed that Aurora A, LC3B, NPM, p53, EGFR, Sp1, Fli-1, Galectin-3 and GSK3B were bowed significantly association with WHO grade and survival time. Multiple regression analyzed Sp1, Fli-1, Galectin-3 and GSK3B were found to be an independent prognosis biomarker. With siRNA in astrocytoma cell lines, knock-down Sp1, Fli-1, Galectin-3 and GSK3B attenuated astrocytoma cells proliferation, migration, and invasion. Western blot showed that broke of the protein expressions of Sp1, Fli-1, Galectin-3 and GSK3B inhibited the protein expressions of Ki-67, cyclin D1, and VEGF. These data surported Aurora A, LC3B, NPM, p53, EGFR, Sp1, Fli-1, Galectin-3 and GSK3B were significantly associated with WHO tumor grade and survival time, whereas Sp1, Fli-1, Galectin-3 and GSK3B were an independent prognostic factor for astrocytoma. In the future, Sp1, Fli-1, Galectin-3 and GSK3B may be as target protein to treat astrocytoma.